Clerkenwell Health is expanding its pan-European advisory board with the addition of Dr David Erritzoe, Dr Dea Siggaard Stenbæk, Dr Kim Kuypers and Dr James Stone...
UK-based Beckley Psytech and drug discovery company Lophora ApS will be researching New Clinical Entities (NCE’s) to bolster a pipeline of next-generation psychedelic medicines.
UK-startup Clerkenwell Health is opening Europe’s first ever facility to host commercial psychedelic clinical trials in London.
As research into psychedelics continues to grow, a new peer reviewed scientific journal – Psychedelic Medicine – will be launched in 2023 to provide a high-profile...
Pharmadrug has announced it is advancing its opthalmology programme with the selection of its lead DMT analogue as a potential treatment for primary open angle glaucoma...
CYB004 – which is being developed for anxiety disorders – has shown that it has a similar onset of effect and dose profile to IV DMT...
In vivo findings have demonstrated that the amanita muscaria extract – AME-1 – indicate a potential priming effect on the immune system, allowing it to more...
Albert Labs has appointed Professor Robert Britton and Dr Ricardo Jorge Dinis-Oliveira to its scientific advisory board (SAB).
With growing scientific interest in the area of psychedelics, Duke University has launched the Center for Integrated Psychedelic Science (CIPS).
Cybin has partnered with Clinilabs to carry out its Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analogue.
